US Patents With Foreign Priority to Germany Patent: 103 19 612
✉ Email this page to a colleague
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msd | PREVYMIS | letermovir | PELLETS;ORAL | 219104-001 | Aug 30, 2024 | RX | Yes | No | RE46791 | ⤷ Get Started Free | Y | Y | |||
| Msd | PREVYMIS | letermovir | PELLETS;ORAL | 219104-002 | Aug 30, 2024 | RX | Yes | Yes | RE46791 | ⤷ Get Started Free | Y | Y | |||
| Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-001 | Nov 8, 2017 | RX | Yes | Yes | RE46791 | ⤷ Get Started Free | Y | Y | |||
| Merck Sharp Dohme | PREVYMIS | letermovir | SOLUTION;INTRAVENOUS | 209940-002 | Nov 8, 2017 | RX | Yes | Yes | RE46791 | ⤷ Get Started Free | Y | Y | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
